Orion Oyj (OTCMKTS:ORINY) Raises Dividend to $0.45 Per Share

Orion Oyj (OTCMKTS:ORINY) declared a dividend on Monday, March 17th, NASDAQ Dividends reports. Investors of record on Monday, April 7th will be given a dividend of 0.4478 per share on Tuesday, April 29th. The ex-dividend date of this dividend is Monday, April 7th. This is a 86.2% increase from Orion Oyj’s previous dividend of $0.24.

Orion Oyj Stock Performance

Shares of OTCMKTS ORINY remained flat at $29.76 during mid-day trading on Tuesday. 115 shares of the stock traded hands, compared to its average volume of 3,410. Orion Oyj has a 12 month low of $17.50 and a 12 month high of $30.25. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. The firm’s fifty day moving average price is $26.81 and its two-hundred day moving average price is $25.49. The firm has a market cap of $8.40 billion, a P/E ratio of 23.62 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 earnings per share (EPS) for the quarter. The firm had revenue of $463.41 million for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. As a group, equities research analysts predict that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a research note on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.